Journal: Cell reports

Article Title: Chromatin Landscape Underpinning Human Dendritic Cell Heterogeneity

doi: 10.1016/j.celrep.2020.108180

Figure Lengend Snippet:

Article Snippet: Anti-human CD127/IL-7R (clone A019D5) Sm149 , Fluidigm , Cat# 3149011B; RRID:AB_2661792.

Techniques: Purification, Recombinant, Produced, SYBR Green Assay, Saline, Lysis, Electron Microscopy, Labeling, Staining, Cell Isolation, Enzyme-linked Immunosorbent Assay, Control, Antibody Labeling, Reverse Transcription, DNA Library Preparation, Generated, Microarray, Software

Journal: Heliyon

Article Title: Atrial fibrillation recurrence after catheter ablation is associated with RAD51 and p63 proteins

doi: 10.1016/j.heliyon.2024.e32874

Figure Lengend Snippet: Images of the microarrays from a representative slide of Explorer antibody microarray (ASB600, Full Moon Biosystems, USA) with 656 antibodies per slide in two replicates for each antibody. Enlarged images of individual samples illustrate the differences in the levels of RAD51 in the serum of a patient with compensated AF of the subgroup M1 (A) versus that in the serum of a patient with AF recurrence of the subgroup M2 (B).

Article Snippet: Images of the microarrays from a representative slide of Explorer antibody microarray (ASB600, Full Moon Biosystems, USA) with 656 antibodies per slide in two replicates for each antibody.

Techniques: Microarray

Journal: Heliyon

Article Title: Atrial fibrillation recurrence after catheter ablation is associated with RAD51 and p63 proteins

doi: 10.1016/j.heliyon.2024.e32874

Figure Lengend Snippet: Images of the microarrays from a representative slide of Explorer antibody microarray (ASB600, Full Moon Biosystems, USA) with 656 antibodies per slide in two replicates for each antibody. Enlarged images of individual samples illustrate the differences in the levels of p63 in the serum of a patient with compensated AF of the subgroup M1 (A) versus that in the serum of a patient with AF recurrence of the subgroup M2 (B).

Article Snippet: Images of the microarrays from a representative slide of Explorer antibody microarray (ASB600, Full Moon Biosystems, USA) with 656 antibodies per slide in two replicates for each antibody.

Techniques: Microarray

Journal: Clinical Proteomics

Article Title: Current applications of antibody microarrays

doi: 10.1186/s12014-018-9184-2

Figure Lengend Snippet: Review of planar antibody microarray technologies and their applications in the field of proteomics. Images were adopted from Servier Medical Art by Servier ( http://www.servier.com/Powerpoint-image-bank ) and modified by the authors under the following terms: CREATIVE COMMONS Attribution 3.0 Unported (CC BY 3.0)

Article Snippet: Fullmoon Biosystems Inc , Prostate cancer , Phosphorylation-specific antibody microarray , 95 , 24009409.

Techniques: Microarray, Modification

Journal: Clinical Proteomics

Article Title: Current applications of antibody microarrays

doi: 10.1186/s12014-018-9184-2

Figure Lengend Snippet: Antibody microarray summary

Article Snippet: Fullmoon Biosystems Inc , Prostate cancer , Phosphorylation-specific antibody microarray , 95 , 24009409.

Techniques: Microarray, Phospho-proteomics, Infection, Biomarker Discovery, Virus

Journal: Biomedicines

Article Title: The Enhanced Expression of ZWILCH Predicts Poor Survival of Adrenocortical Carcinoma Patients.

doi: 10.3390/biomedicines11041233

Figure Lengend Snippet: Figure 1. An overall survival area plot showing different estimates of the causal effect of the ZWILCH expression on survival using different Cox proportional hazards regression models (A). The contour plot illustrates the probability of patient survival over time according to ZWILCH gene expression level in ACC patients from the TCGA database (B).

Article Snippet: Slides were immersed in Target Retrieval Solution, Citrate pH 6.1 (#H-3300-250, Vector, Stuttgart, Germany), and heated in a microwave for 5 min. After that, they were cooled down to room temperature (RT) for 20 min. After endogenous peroxidase activity blocking and incubation with 2.5% normal horse serum, the sections were incubated with anti-ZWILCH polyclonal rabbit antibody (#14281-1-AP, Proteintech, Rosemont, IL, USA) with 1:1000 concentration at 4 ◦C overnight.

Techniques: Expressing, Gene Expression

Journal: Biomedicines

Article Title: The Enhanced Expression of ZWILCH Predicts Poor Survival of Adrenocortical Carcinoma Patients.

doi: 10.3390/biomedicines11041233

Figure Lengend Snippet: Figure 5. General transcriptome profile in groups of 10 patients with the highest expression of the ZWILCH gene (up ZWILCH) compared to 10 patients with the lowest expression of the ZWILCH gene (down ZWILCH) (data from GSE10927). Each dot on the graph represents the mean value of the gene expression level of ten patients belonging to a particular group. The cut-off criteria for identifying differentially expressed genes were established as |fold change| = 1.5 and p-value = 0.05, and are represented by orange dotted lines. Genes above the cut-off lines were categorized as up−regulated (green dots) or down−regulated (red dots). The total number of up−and down−regulated genes can be found in the top right and top left corners, respectively. The plots also indicate the symbols for the seven most differentially expressed genes.

Article Snippet: Slides were immersed in Target Retrieval Solution, Citrate pH 6.1 (#H-3300-250, Vector, Stuttgart, Germany), and heated in a microwave for 5 min. After that, they were cooled down to room temperature (RT) for 20 min. After endogenous peroxidase activity blocking and incubation with 2.5% normal horse serum, the sections were incubated with anti-ZWILCH polyclonal rabbit antibody (#14281-1-AP, Proteintech, Rosemont, IL, USA) with 1:1000 concentration at 4 ◦C overnight.

Techniques: Expressing, Gene Expression

Journal: Biomedicines

Article Title: The Enhanced Expression of ZWILCH Predicts Poor Survival of Adrenocortical Carcinoma Patients.

doi: 10.3390/biomedicines11041233

Figure Lengend Snippet: Figure 8. Gene set enrichment analysis (GSEA) from the comparison of patients with low and high ZWILCH expression, based on GSE10927. Clustering of enriched gene sets into common functional groups, each cluster is marked with a different color (A). The barplot with ten of the most activated and inhibited gene terms according to the normalized enrichment score values (B). Detailed enrichment plots for the five most inhibited and the five most activated gene sets, showing the profile of the running NES score and the positions of the genes on the rank−ordered list (C,D).

Article Snippet: Slides were immersed in Target Retrieval Solution, Citrate pH 6.1 (#H-3300-250, Vector, Stuttgart, Germany), and heated in a microwave for 5 min. After that, they were cooled down to room temperature (RT) for 20 min. After endogenous peroxidase activity blocking and incubation with 2.5% normal horse serum, the sections were incubated with anti-ZWILCH polyclonal rabbit antibody (#14281-1-AP, Proteintech, Rosemont, IL, USA) with 1:1000 concentration at 4 ◦C overnight.

Techniques: Comparison, Expressing, Functional Assay

Journal: Biomedicines

Article Title: The Enhanced Expression of ZWILCH Predicts Poor Survival of Adrenocortical Carcinoma Patients.

doi: 10.3390/biomedicines11041233

Figure Lengend Snippet: Figure 10. The expression of ZWILCH protein in human adrenal gland disease spectrum (adrenal cancer progression) tissue microarray (TMA) slide. The general profile of immunohistochemical staining presents localization of ZWILCH protein (A). TMA map shows the relevant types of adrenal cancer progression marked in an appropriate color (B). Densitometric analysis of ZWILCH gene expression in the tissue array side of the adrenal gland disease spectrum. The boxplot displays each group with its median and interquartile range (IQR) (C). Individual patient densitometric data were added to the corresponding boxplots and represented as dots. The Kruskal–Wallis (KW) test was used to compare groups, followed by the Dunn post hoc test. Differences between groups were marked with asterisks: ** for p < 0.01. Letter annotation was used to indicate statistically significant differences (p < 0.05) between compared groups. Paired comparisons with post hoc Dunn p-values are also shown in the table.

Article Snippet: Slides were immersed in Target Retrieval Solution, Citrate pH 6.1 (#H-3300-250, Vector, Stuttgart, Germany), and heated in a microwave for 5 min. After that, they were cooled down to room temperature (RT) for 20 min. After endogenous peroxidase activity blocking and incubation with 2.5% normal horse serum, the sections were incubated with anti-ZWILCH polyclonal rabbit antibody (#14281-1-AP, Proteintech, Rosemont, IL, USA) with 1:1000 concentration at 4 ◦C overnight.

Techniques: Expressing, Microarray, Immunohistochemical staining, Staining, Gene Expression

Journal: Biomedicines

Article Title: The Enhanced Expression of ZWILCH Predicts Poor Survival of Adrenocortical Carcinoma Patients.

doi: 10.3390/biomedicines11041233

Figure Lengend Snippet: Figure 11. Representative immunostaining of adrenal gland disease spectrum (adrenal cancer pro- gression) TMA slide. Brown staining (B,C,E,F,H,I,K,L,N,O) indicates ZWILCH protein (red arrows), located typically cellular with hematoxylin counterstain (nucleus). The negative control of adrenal gland tissue (A,D,G,J,L,M). Original magnification was 100× (A,B,D,E,G,H,M,N), 200× (J,L,K), and 400× (C,F,I,L,O).

Article Snippet: Slides were immersed in Target Retrieval Solution, Citrate pH 6.1 (#H-3300-250, Vector, Stuttgart, Germany), and heated in a microwave for 5 min. After that, they were cooled down to room temperature (RT) for 20 min. After endogenous peroxidase activity blocking and incubation with 2.5% normal horse serum, the sections were incubated with anti-ZWILCH polyclonal rabbit antibody (#14281-1-AP, Proteintech, Rosemont, IL, USA) with 1:1000 concentration at 4 ◦C overnight.

Techniques: Immunostaining, Staining, Negative Control

Journal: PLoS Genetics

Article Title: Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma

doi: 10.1371/journal.pgen.1004877

Figure Lengend Snippet: A , Scheme showing the localization of epidermal melanocytes (in red) in the human skin. B, C , Immunostaining for MITF (green, left panel) and SOX9 (red, right panel) in the human skin demonstrating the lack of SOX9 expression in the epidermal melanocytes. Inserts show higher magnification images of MITF and SOX9 immunostainings. Scale bars, 25 μm. D , Scheme showing the localization of melanocytes (in red) within the hair follicle. E , Immunostaining for MITF (green) and SOX9 (red) in the human skin reveals the expression of SOX9 in the cells of outer root sheath but not in the MITF-positive melanoblasts/melanocytes. Scale bar 100 μm. F, G , High magnification images of immunostaining for MITF and SOX9 in the upper part of human hair follicle ( F ) and the follicular bulb ( G ). H , Analysis of SOX9 (red, left panel) and SOX10 (red, right panel) expression in the patients with human giant congenital naevi demonstrates the lack of SOX9 expression in the SOX10-positive giant congenital naevi cells. Inserts show higher magnification. I , Representative examples of immunostaining for SOX9 (green) and SOX10 (red) in a tissue microarray of primary melanoma samples are shown. J-K , Distribution of SOX10 vs. SOX9 expression in human melanoma (based on TCGA database). 334 melanoma patients were divided in two groups, namely SOX10 High/ SOX9 Low and SOX10 Low / SOX9 high based on SOX10 and SOX9 expression levels. DP, dermal papilla; HF, hair follicle; M, melanocytes; ORS, outer root sheath. Scale bars, 25 μm.

Article Snippet: The following primary antibodies were used: anti-Sox10 (goat, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Sox10 (mouse, 1:200, R&D), anti-Sox9 (rabbit, 1:100, sc-20095, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Sox9 (rabbit, 1:100, ab36748, Abcam), anti-Sox9 (M00006662, Abnova), anti-Sox9 (AB5535, Millipore), anti-Sox9 (GTX 109661, GenTex), anti-MITF (mouse, clone 6D3, 1:500) was a kind gift from Heinz Arnheiter (NIH, USA).

Techniques: Immunostaining, Expressing, Microarray

Journal: PLoS Genetics

Article Title: Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma

doi: 10.1371/journal.pgen.1004877

Figure Lengend Snippet: A , A schematic representation of the experimental strategy used to analyze the expression of Sox9, Sox10, Mitf and Tyr genes in the melanocytic lineage in vivo . B , Results of RNA-seq analysis demonstrating high Sox10 and low Sox9 expression in melanocytic cells at various stages of development. C , A schematic representation of the anatomical location of the melanocyte stem cells, melanoblasts and differentiated melanocytes within the hair follicle in the mouse skin. D , X-Gal staining (blue) combined with Sox9 immunostaining (red) in skin sections of Dct::LacZ mice demonstrating the lack of the Sox9 expression in the melanocyte stem cells located in the bulge region of the hair follicle (upper panels) and in the differentiated melanocytes located in the hair follicular bulb (lower panels). E , Skin sections of Dct::LacZ mice stained for Sox10 (red) in combination with X-Gal staining (blue) reveal the expression of Sox10 in the melanocyte stem cells (upper panels) as well as in the differentiated melanocytes (lower panels). Dashed lines demarcate HFs. Insets show high magnification views. F-I , Experimental strategy used to analyze the effect of the lack of Sox9 ( F ) and Sox10 ( H ) expression in the mouse melanocytic lineage. Pictures of two representative mice at 6 months of age lacking Sox9 gene ( G ) and Sox10 gene ( I ) demonstrating the effects on hair graying. Bg, bulge; HF, hair follicle; MSCs, melanocyte stem cells; Mo, months; E 15.5, embryonic day 15.5; P0, postnatal day 0; SG, sebaceous gland. Scale bars, 25 μm.

Article Snippet: The following primary antibodies were used: anti-Sox10 (goat, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Sox10 (mouse, 1:200, R&D), anti-Sox9 (rabbit, 1:100, sc-20095, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Sox9 (rabbit, 1:100, ab36748, Abcam), anti-Sox9 (M00006662, Abnova), anti-Sox9 (AB5535, Millipore), anti-Sox9 (GTX 109661, GenTex), anti-MITF (mouse, clone 6D3, 1:500) was a kind gift from Heinz Arnheiter (NIH, USA).

Techniques: Expressing, In Vivo, RNA Sequencing Assay, Staining, Immunostaining

Journal: PLoS Genetics

Article Title: Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma

doi: 10.1371/journal.pgen.1004877

Figure Lengend Snippet: A-D , Immunostaining for Sox9 ( A, C ) and Sox10 ( B, D ) in the skin sections of Tyr::Nras Q61K and Tyr::Nras Q61K INK4a −/− mice. E-H , Experimental strategy used to abrogate the expression of Sox9 (E) and Sox10 (G) in the mouse melanocytic lineage. Pictures of two representative mice 1 year after tamoxifen injections reveal no reduction in the skin hyperpigmentation in Tyr::Nras Q61K Sox9 fl/+ Tyr-CreERT2 mice as compared to their Tyr::Nras Q61K littermates (F) in contrast to a pronounced skin whitening observed upon Sox10 loss (H). BF, bright field; HF, hair follicle; mo, months; P0, postnatal day 0. Scale bars, 25 μm.

Article Snippet: The following primary antibodies were used: anti-Sox10 (goat, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Sox10 (mouse, 1:200, R&D), anti-Sox9 (rabbit, 1:100, sc-20095, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Sox9 (rabbit, 1:100, ab36748, Abcam), anti-Sox9 (M00006662, Abnova), anti-Sox9 (AB5535, Millipore), anti-Sox9 (GTX 109661, GenTex), anti-MITF (mouse, clone 6D3, 1:500) was a kind gift from Heinz Arnheiter (NIH, USA).

Techniques: Immunostaining, Expressing

Journal: PLoS Genetics

Article Title: Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma

doi: 10.1371/journal.pgen.1004877

Figure Lengend Snippet: A , Experimental design used to investigate the level of SOX9 and SOX10 expression in vitro . Cultured human keratinocytes, melanocytes, cells derived from biopsies of patients with giant congential naevi and melanoma cells (M010817 cell line) were subjected to RNA isolation and subsequent Q-RT-PCR analysis. Keratinocytes were used as a control. B, C , Quantitative real-time PCR analysis showing the decline of SOX9 expression ( C ) and increase of SOX10 expression ( B ) that correlate with the acquisition of malignant state by human NRAS Q61K -mutated cells. Data are presented as the mean fold change and are normalized over levels found in melanocytes. D, E , SOX10 and SOX9 expression in a large set of proliferative and invasive cell lines analysed by gene expression using microarrays ( D ) and Western blot ( E ) techniques. F , Experimental design used to deregulate SOX10 expression in human cells derived from the biopsy of a patient with NRAS Q61K -mutated giant congenital naevus. G, H , Quantitative real-time PCR analysis of SOX10 ( G ) and SOX9 ( H ) expression after the knockdown of SOX10. I , Experimental design used to analyze the expression of Sox9 in the melanocytic lineage from Tyr::Nras Q61K and Tyr::Nras Q61K Sox10 LacZ/+ mice. K, L , Cells were isolated from the trunk skin of Tyr::Nras Q61K and Tyr::Nras Q61K Sox10 LacZ/+ mice and stained for Melan-a and c-Kit antibodies. FACS-sorted cells were subsequently used for the RNA isolation and quantitative real-time PCR with primers specific for the coding regions of Sox9 gene. Data are presented as the mean fold change and are normalized to the control. Kerat, keratinocytes; M, melanocytes; Nev, naevus cells; Mel, melanoma cells; KD, knock down.

Article Snippet: The following primary antibodies were used: anti-Sox10 (goat, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Sox10 (mouse, 1:200, R&D), anti-Sox9 (rabbit, 1:100, sc-20095, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Sox9 (rabbit, 1:100, ab36748, Abcam), anti-Sox9 (M00006662, Abnova), anti-Sox9 (AB5535, Millipore), anti-Sox9 (GTX 109661, GenTex), anti-MITF (mouse, clone 6D3, 1:500) was a kind gift from Heinz Arnheiter (NIH, USA).

Techniques: Expressing, In Vitro, Cell Culture, Derivative Assay, Isolation, Reverse Transcription Polymerase Chain Reaction, Real-time Polymerase Chain Reaction, Western Blot, Staining

Journal: PLoS Genetics

Article Title: Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma

doi: 10.1371/journal.pgen.1004877

Figure Lengend Snippet: A , SOX9 overexpression in human melanoma cells closely resembles the gene expression signature of SOX10 knockdown as revealed by unsupervised hierarchical clustering of control M010817 melanoma cells, SOX9 overexpressing M010817 cells and SOX10 knock down M010817 cells. Microarray gene expression accession number: GSE37059. B , Western blot analysis showing that SOX10 expression is downregulated upon overexpression of SOX9 in two independent human melanoma cell lines (A375 and M010817). C , Chromatin immunoprecipitation assay demonstrating the binding of SOX9 to the promoter of SOX10 in human melanoma M010817 cells. D, E , Quantitative real-time PCR analysis of SOX10 ( E ) and SOX9 ( F ) expression after the knockdown of SOX10 and after the double knockdown of SOX10 and SOX9 in M010817 cell line. F , Quantification of number of Annexin V-positive cells based on the FACS analysis in the melanoma M010817 cells upon SOX9 KD, SOX10 KD or double SOX9/SOX10 KD. OE, overexpression; KD, knock down; ChIP, chromatin immunoprecipitation; prom, promoter.

Article Snippet: The following primary antibodies were used: anti-Sox10 (goat, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Sox10 (mouse, 1:200, R&D), anti-Sox9 (rabbit, 1:100, sc-20095, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Sox9 (rabbit, 1:100, ab36748, Abcam), anti-Sox9 (M00006662, Abnova), anti-Sox9 (AB5535, Millipore), anti-Sox9 (GTX 109661, GenTex), anti-MITF (mouse, clone 6D3, 1:500) was a kind gift from Heinz Arnheiter (NIH, USA).

Techniques: Over Expression, Expressing, Microarray, Western Blot, Chromatin Immunoprecipitation, Binding Assay, Real-time Polymerase Chain Reaction

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Cellular retinol binding protein 1 could be a tumor suppressor gene in cervical cancer

doi:

Figure Lengend Snippet: Molecular events for CRBP1 gene in cervical epithelium samples. A: In order to know the gain of copy number of the CRBP1 gene, DNA of healthy cervix and CC samples, were subjected to real time PCR with specific Taqman probes. White bar (healthy cervix samples) represents the mean of the normal cervices (n = 26) without extra copies of CRBP1 gene. Black bars show CC samples with gain of copy number (2-20X); while gray dotted line bars are showing CC samples that do not change in the copies number. Values above the cut-off line (as 1), being assigned as increased gene copy number compared with normal cervical epithelium. CRBP1 Hs01437985_cn probe, and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Hs00894322_cn probe were used as reference; the relative genomic copy number was calculated using the comparative Ct methods [26]. In X-axis represents cervical samples, Y-axis relative copies fold change of CRBP1 gene. B: CRBP1 expression was observed as positive immunostaining result on tissue microarray as mentioned in Methods section The DNAs used for gain of copy number (panel A) were also used for the methylation assay. Methylation result represents the methylation of the CRBP1 promoter. In this case, each healthy or CC sample, correspond to each column for CRBP1 expression and methylation status. Interestingly, in most of the cases, there was an association between the lack of expression of the CRBP1 gene and its methylation status.

Article Snippet: Incubation with the monoclonal mouse anti-CRBP1 antibody (ab24090 Abcam) was performed overnight at 4°C, at 1:100 dilution in 1% bovine serum albumin in phosphate buffered saline (PBS).

Techniques: Real-time Polymerase Chain Reaction, Expressing, Immunostaining, Microarray, Methylation

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Cellular retinol binding protein 1 could be a tumor suppressor gene in cervical cancer

doi:

Figure Lengend Snippet: CRBP1 immunodetection in the uterine cervix samples. A: (1) Cytoplasmic CRBP1 expression is present in cells of the basal layer of normal cervical epithelium (healthy tissue); (2) the immunodetection in the transformed cells of a cervical cancer (CC03) tissue harboring gain of CRBP1 gene. (3) CC samples without gain CRBP1 gene showing negative immunostaining (CC16 sample). A kidney tissue section (4) was used as positive control, while a heart tissue section for negative control (5). B: cervical progression spectrum. The tissue section shows a brownish reaction (positive reaction) in the basal cell layer of the “normal” region, in the high-grade lesion, and also in the invasive region. All tissue sections were hematoxylin counterstained, 200X original amplification.

Article Snippet: Incubation with the monoclonal mouse anti-CRBP1 antibody (ab24090 Abcam) was performed overnight at 4°C, at 1:100 dilution in 1% bovine serum albumin in phosphate buffered saline (PBS).

Techniques: Immunodetection, Expressing, Transformation Assay, Immunostaining, Positive Control, Negative Control, Amplification

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Cellular retinol binding protein 1 could be a tumor suppressor gene in cervical cancer

doi:

Figure Lengend Snippet: Association between CRBP1 gene gain copy number and its expression in cervical cancer samples

Article Snippet: Incubation with the monoclonal mouse anti-CRBP1 antibody (ab24090 Abcam) was performed overnight at 4°C, at 1:100 dilution in 1% bovine serum albumin in phosphate buffered saline (PBS).

Techniques: Expressing, Immunodetection

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Cellular retinol binding protein 1 could be a tumor suppressor gene in cervical cancer

doi:

Figure Lengend Snippet: Correlation between CRBP1 expression and clinic pathological variables in cervical cancer

Article Snippet: Incubation with the monoclonal mouse anti-CRBP1 antibody (ab24090 Abcam) was performed overnight at 4°C, at 1:100 dilution in 1% bovine serum albumin in phosphate buffered saline (PBS).

Techniques: Expressing, Activity Assay

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Cellular retinol binding protein 1 could be a tumor suppressor gene in cervical cancer

doi:

Figure Lengend Snippet: Immunolocalization of CRBP1 by immunofluorescence in cervical cells. Nuclei were Dapi stained in blue color (A-C). The immunodetection of CRBP1 was observed in green color (D-F). Cytoplasmic immunodetection of CRBP1 in the merge imaging (G-I). 100X original amplification.

Article Snippet: Incubation with the monoclonal mouse anti-CRBP1 antibody (ab24090 Abcam) was performed overnight at 4°C, at 1:100 dilution in 1% bovine serum albumin in phosphate buffered saline (PBS).

Techniques: Immunofluorescence, Staining, Immunodetection, Imaging, Amplification

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Cellular retinol binding protein 1 could be a tumor suppressor gene in cervical cancer

doi:

Figure Lengend Snippet: Methylation promoter of CRBP1 gene in cervical cancer samples. Example of CRBP1 gene promoter methylation analysis. Lanes: Healthy cervix sample, CC03 and CC06 samples with un-methylated status; lanes CC 10 and CC 16 with methylated status; HeLa cells as un-methylated control (109 bp), or MCF-7 cells as methylated control (99 bp). MW: molecular weight marker of 100 bp.

Article Snippet: Incubation with the monoclonal mouse anti-CRBP1 antibody (ab24090 Abcam) was performed overnight at 4°C, at 1:100 dilution in 1% bovine serum albumin in phosphate buffered saline (PBS).

Techniques: Methylation, Molecular Weight, Marker